William J. Burman - Concepedia

Author

William J. Burman

Also Known As

Carol Brosgart, WILLIAM J. BURMAN, WILLIAM J. BURMAN, William J. Burman, William BURMAN, William Burman, William J Burman, William J. BURMAN, William J. Burman, William J. Burman

163

Publications

9.6K

Citations

H-Index

113

Concepts

All Affiliations

Denver Public Health University of Colorado Denver Denver Health Medical Center University of Colorado Health Centers for Disease Control and Prevention

About

William J. Burman is an author at Denver Public Health specializing in medicine, drug resistance, and tuberculosis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	32	2.7K
2	Health Sciences	7	7	557
3	Education	2	2	186
4	Arts	1	1	34
5	Law	1	1	48

William J. Burman

Publications

7.3K

Citations

H-Index

Page 1

	Year	Citations
High Sensitivity of Human Leukocyte Antigen–B*5701 as a Marker for Immunologically Confirmed Abacavir Hypersensitivity in White and Black Patients Michael S. Saag, Rukmini Balu, Elizabeth J. Phillips, Clinical Infectious Diseases	2008	429
Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial Debra Benator, Mondira Bhattacharya, Lorna Bozeman, The Lancet Pulmonary TuberculosisTreatment And PreventionMedicineRandomised Clinical TrialWeek Versus Rifampicin	2002	408
Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid Andrew Vernon, William J. Burman, Debra Benator, The Lancet AntibioticsHiv-related TuberculosisTuberculosisAntimicrobial ChemotherapyAcquired Rifamycin Monoresistance	1999	309
Recreational drug use, polydrug use, and sexual behaviour in HIV-diagnosed men who have sex with men in the UK: results from the cross-sectional ASTRA study Marina Daskalopoulou, Alison Rodger, Andrew Phillips, The Lancet HIV	2014	305
Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary Tuberculosis William J. Burman, Stefan Goldberg, John L. Johnson, American Journal of Respiratory and Critical Care Medicine	2006	284
Interruption of Antiretroviral Therapy and Risk of Cardiovascular Disease in Persons with HIV-1 Infection: Exploratory Analyses from the SMART Trial Andrew Phillips, Andrew Carr, Jacquie Neuhaus, Antiviral Therapy	2008	243
Impact of Routine Infectious Diseases Service Consultation on the Evaluation, Management, and Outcomes of <i>Staphylococcus aureus</i> Bacteremia Timothy C Jenkins, Connie Price, Allison L. Sabel, Clinical Infectious Diseases	2008	213
Low Isoniazid Concentrations and Outcome of Tuberculosis Treatment with Once-Weekly Isoniazid and Rifapentine Marc Weiner, William J. Burman, Andrew Vernon, American Journal of Respiratory and Critical Care Medicine	2003	192
Noncompliance With Directly Observed Therapy for Tuberculosis William J. Burman, David L. Cohn, Cornelis A. Rietmeijer, CHEST Journal Pulmonary TuberculosisDirectly Observed TherapyTuberculosis PreventionEvidence-based MedicineTuberculosis	1997	187
Skin and Soft‐Tissue Infections Requiring Hospitalization at an Academic Medical Center: Opportunities for Antimicrobial Stewardship Timothy C Jenkins, Allison L. Sabel, Ellen Sarcone, Clinical Infectious Diseases	2010	180

Page 1